Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB103 with Standard Treatment in Advanced NSCLC
NCT04616209Phase 2Recruiting
- Sponsor
- Precision BioSciences, Inc.
- Start
- Nov 2020
- Primary completion
- Dec 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of PB 103 in non-small cell lung cancer (NSCLC), sponsored by Precision BioSciences, Inc.. Started Nov 2020; status: recruiting.
02
Drugs
PB 103
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04616209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616209.